Understand Pharma, a San Francisco, CA-based pharmaceutical firm advancing novel small molecule therapeutics in ophthalmology, raised $15M in Sequence A funding.
The spherical was led by Deerfield Administration, Johnson & Johnson, Braidwell LP, GV, the Retinal Degeneration Fund, and Catalio Capital Administration, LP.
Led by CEO Ok. Angela Macfarlane, Understand Pharma is advancing novel small molecule neuroprotective therapeutics, with lead pipeline packages in glaucoma and different ophthalmic ailments. The corporate is targeted on the neuroprotective pathways first elucidated in a genomic screening by co-founders Drs. Don Zack and Derek Welsbie, who additional collaborated with a key business companion to place Understand Pharma with a library of neuroprotective drug candidates, together with its lead therapeutic candidate, PBI-671.
Sequence A proceeds will advance the event of first-in-class therapies to forestall imaginative and prescient loss in glaucoma, and extra undisclosed illness areas.
Spun out from Understand Biotherapeutics, Inc., Understand Pharma additionally introduced that Carol Gallagher, Pharm.D. has joined the corporate’s Board of Administrators as an unbiased director.
FinSMEs
18/02/2025
